225 related articles for article (PubMed ID: 16289523)
41. Estimating drug treatment needs among state prison inmates.
Belenko S; Peugh J
Drug Alcohol Depend; 2005 Mar; 77(3):269-81. PubMed ID: 15734227
[TBL] [Abstract][Full Text] [Related]
42. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
43. The role of public health agencies in providing access to adolescent drug treatment services.
VanderWaal CJ; McBride DC; Terry-McElrath YM; Bishop RM
J Adolesc Health; 2006 Dec; 39(6):916-24. PubMed ID: 17116524
[TBL] [Abstract][Full Text] [Related]
44. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes.
Heinzerling KG; Kral AH; Flynn NM; Anderson RL; Scott A; Gilbert ML; Asch SM; Bluthenthal RN
J Subst Abuse Treat; 2007 Jun; 32(4):423-9. PubMed ID: 17481466
[TBL] [Abstract][Full Text] [Related]
45. HIV prevention for injecting drug users: the first 25 years and counting.
Des Jarlais DC; Semaan S
Psychosom Med; 2008 Jun; 70(5):606-11. PubMed ID: 18519886
[TBL] [Abstract][Full Text] [Related]
46. Provision of hepatitis C education in a nationwide sample of drug treatment programs.
Astone J; Strauss SM; Vassilev ZP; Des Jarlais DC
J Drug Educ; 2003; 33(1):107-17. PubMed ID: 12773028
[TBL] [Abstract][Full Text] [Related]
47. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users--new York, November 2004-April 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 May; 57(19):517-21. PubMed ID: 18480744
[TBL] [Abstract][Full Text] [Related]
48. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study.
Jauffret-Roustide M; Emmanuelli J; Quaglia M; Barin F; Arduin P; Laporte A; Desenclos JC
Subst Use Misuse; 2006; 41(10-12):1603-21. PubMed ID: 17002994
[TBL] [Abstract][Full Text] [Related]
49. Access to health and social services for IDU: the impact of a medically supervised injection facility.
Small W; Van Borek N; Fairbairn N; Wood E; Kerr T
Drug Alcohol Rev; 2009 Jul; 28(4):341-6. PubMed ID: 19594786
[TBL] [Abstract][Full Text] [Related]
50. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units.
Strauss SM; Astone JM; Des Jarlais DC; Hagan H
AIDS Patient Care STDS; 2005 Feb; 19(2):78-88. PubMed ID: 15716639
[TBL] [Abstract][Full Text] [Related]
51. Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs.
Munoz-Plaza CE; Strauss SM; Astone-Twerwll JM; Des Jarlais DC; Hagan H
J Psychoactive Drugs; 2006 Sep; 38(3):233-41. PubMed ID: 17165366
[TBL] [Abstract][Full Text] [Related]
52. The impact of HIV infection on medical services in drug abuse treatment programs.
Selwyn PA
J Subst Abuse Treat; 1996; 13(5):397-410; discussion 439. PubMed ID: 9142670
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis services at an injecting drug user outreach clinic.
Moriarty H; Kemp R; Robinson G
N Z Med J; 2001 Mar; 114(1128):105-6. PubMed ID: 11346154
[TBL] [Abstract][Full Text] [Related]
54. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.
Reimer J; Schulte B; Castells X; Schafer I; Polywka S; Hedrich D; Wiessing L; Haasen C; Backmund M; Krausz M
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S373-8. PubMed ID: 15768351
[TBL] [Abstract][Full Text] [Related]
55. Gaps in the drug-free and methadone treatment program response to Hepatitis C.
Strauss SM; Astone J; Vassilev ZP; Des Jarlais DC; Hagan H
J Subst Abuse Treat; 2003 Jun; 24(4):291-7. PubMed ID: 12867202
[TBL] [Abstract][Full Text] [Related]
56. Hepatitis C virus prevention, care, and treatment: from policy to practice.
Ward JW; Valdiserri RO; Koh HK
Clin Infect Dis; 2012 Jul; 55 Suppl 1():S58-63. PubMed ID: 22715216
[TBL] [Abstract][Full Text] [Related]
57. Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.
Aletraris L; Roman PM
J Subst Abuse Treat; 2015 Oct; 57():1-8. PubMed ID: 25934459
[TBL] [Abstract][Full Text] [Related]
58. Tuberculosis treatment through directly observed therapy in a large multisite methadone maintenance treatment program: addressing the public health needs of a high-risk population.
Altarac D; Dansky SF
J Public Health Manag Pract; 1995; 1(4):40-7. PubMed ID: 10186640
[TBL] [Abstract][Full Text] [Related]
59. Missed opportunities for hepatitis C testing in opioid treatment programs.
Frimpong JA
Am J Public Health; 2013 Jun; 103(6):1028-30. PubMed ID: 23597374
[TBL] [Abstract][Full Text] [Related]
60. Trends in injection drug use among persons entering addiction treatment--New Jersey, 1992-1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 May; 50(19):378-81. PubMed ID: 11465905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
